PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
期刊:Clinical Cancer Research
影响因子:10.200
doi:10.1158/1078-0432.CCR-25-1459
Juric Dejan, Song Kyung, Johnson Radia M, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Saura Cristina, Schmid Peter, Turner Nicholas C, Varga Andreea, Gendreau Steven, Hwang Michael S, Kuang Zheng, Lau Jeffrey T, Lin Eva, Pham Trang, Maddalo Danilo, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Martin Scott, Sodir Nicole M, Sokol Ethan S, Whitfield Zachary J, Wong Alice, Yauch Robert L, Aimi Junko, Cheeti Sravanthi, Fredrickson Jill, Hilz Stephanie, Hafner Marc, Hutchinson Katherine E, Jin Yanling, Peters Ubong, Zingg Daniel, Royer-Joo Stephanie, Shankar Noopur, Schutzman Jennifer L, Jhaveri Komal L, Dey Anwesha